Work

Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator (P9-9.011)

Year: 2025

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000211227

Authors: Bharat Awsare, Jason Lerner, Eric Ashbrenner, Heather Sevinsky, Steven Dworetzky, Christopher Jensen, Randall Killingsworth, Andrea Ivans, Irfan Qureshi, Vladimir Coric, Michael Bozik

Institution: Biohaven Pharmaceuticals (United States)

Language: English

Topic: Ion channel regulation and function

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409226565

FWCI:

Cites:

Cited by:

Related to: 10